Inactive Instrument

Saamya Biotech (India) Limited

532905

INE320H01019

Biotechnology & Medical Research

Saamya Biotech Limited Announces the appointment of Mr. Kishan Kumar Srishankar Jha as Additional Director

November 22, 2014 at 01:21 am EST

Saamya Biotech (India) Limited announced that Mr. Kishan Kumar Srishankar Jha, has been appointed as additional director of the company with effect from November 18, 2014.

Latest news about Saamya Biotech (India) Limited

Saamya Biotech India Limited Reports Earnings Results for the First Quarter Ended June 30, 2019	19-08-18	CI
Saamya Biotech Limited Reports Audited Standalone Earnings Results for the Quarter and Year Ended March 31, 2019	19-07-16	CI
Saamya Biotech Limited Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2018	19-02-23	CI
Saamya Biotech Limited Reports Unaudited Earnings Results for the Quarter and Half Year Ended September 30, 2018	19-02-23	CI
Saamya Biotech Limited Reports Audited Earnings Results for Fourth Quarter and Full Year Ended Mar. 31, 2017	17-05-30	CI
Saamya Biotech Limited Approves Address Change	17-03-09	CI
Saamya Biotech Limited Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016	17-02-14	CI
Saamya Biotech Limited Approves Address Change	17-02-14	CI
Saamya Biotech Limited Reports Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2016	16-11-12	CI
Saamya Biotech Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2016	16-08-13	CI
Saamya Biotech Limited Reports Audited Standalone Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2016	16-05-30	CI
Saamya Biotech Limited Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2015	16-02-15	CI
Saamya Biotech Limited Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended September 30, 2015	15-11-12	CI
Saamya Biotech Limited Reports Unaudited Standalone Earnings Results for First Quarter Ended June 30, 2015	15-08-12	CI
Saamya Biotech Limited Announces Board Changes	15-07-06	CI
Saamya Biotech Limited Announces the appointment of Mr. Kishan Kumar Srishankar Jha as Additional Director	14-11-22	CI
Saamya Biotech Limited Reports Unaudited Standalone Earnings Results for Second Quarter and Six Months Ended September 30, 2014	14-11-14	CI
Saamya Biotech Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2014	14-08-13	CI
Saamya Biotech Limited Reports Audited Standalone Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2014	14-06-01	CI
Saamya Biotech Limited Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2013	14-02-14	CI
Saamya Biotech India Ltd Announces Unaudited Earnings Results for the Second Quarter and Half Year Ended September 30, 2013	13-11-13	CI
Saamya Biotech Limited Announces Unaudited Earnings Results for the First Quarter Ended June 30, 2013	13-08-11	CI
Saamya Biotech Limited Announces Audited Earnings Results for the Fourth Quarter and Year Ended March 31, 2013	13-05-29	CI
Saamya Biotech Limited Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2012	13-02-12	CI
Saamya Biotech Limited Reports Unaudited Earnings Results for the Second Quarter and Half Year Ended September 30, 2012	12-11-14	CI

Chart Saamya Biotech (India) Limited

Duration

Period

More charts

Saamya Biotech (India) Limited is an India-based biotechnology company. The Company's principal activity is trading of active pharmaceutical ingredients (API). The Company is engaged in the business of research and development of biotechnology products. The Company focuses on manufacturing and marketing of biopharmaceuticals and recombinant protein products of medical and industrial fields. The Company focuses on setting up of manufacturing facilities with an aggregate installed capacity of 342 kilograms per annum of bulk APIs of biopharmaceuticals. The Company also focuses on manufacturing Daunomycin, Hyaluronic acid (Pharma Grade), Tacrolimus, Rapamycin, Cyclosporin A, Probiotics, Lysergic Acid, Mycophenolic Acid, Clavulenic Acid, Vancomycin, Co-Enzyme Q10, Interferon B and Monoclonal Antibodies (anti-cancer). The Company intends to manufacture biopharmaceuticals in its plant located in Hyderabad, India.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-6.26%	11.42B

Other Biotechnology & Medical Research

Saamya Biotech (India) Limited

Equities

532905

INE320H01019

Biotechnology & Medical Research

Saamya Biotech Limited Announces the appointment of Mr. Kishan Kumar Srishankar Jha as Additional Director

Latest news about Saamya Biotech (India) Limited

Chart Saamya Biotech (India) Limited

Company Profile

Sector Other Biotechnology & Medical Research